Skip to content

Earnings call

Advanced Enzyme Technologies Q4 FY26 earnings call: Advanced Enzyme Technologies Limited expects margins to be steady, with 1% or 2% variability always possible

By . Assembled by software from the company's transcript. Not reviewed by a person.

Transcript filed .

The company expects margins to be steady, with 1% or 2% variability always possible. The company will spend an additional INR 50 crores on CapEx this year, and overall CapEx on R&D will be about INR 130 crores. The company reported its highest-ever quarterly and annual revenue for the fiscal year ended March 2026. Human Healthcare division contributed 63% of its total revenue.

The numbers management gave

Results

  • The company reported its highest-ever quarterly and annual revenue for the fiscal year ended March 2026.
    Show source
    Turning in our financial performance, I'm delighted to announce that Advanced Enzyme has reported its highest-ever quarterly and annual revenue for the fiscal year ended March 2026.
  • The company reported revenue from operation of INR 2,034 million in the quarter ended March 31, 2026, up 22% year-on-year and 18% sequentially.
    Show source
    For the fourth quarter, we reported revenue from operation at INR 2,034 million, reflecting the robust YoY growth of 22% and sequential growth of 18%.
  • The company reported annual revenue of INR 7,458 million for the year ended March 31, 2026, up 17%.
    Show source
    For the full year, our annual revenues stood at INR 7,458 million, representing a solid growth of 17%.
  • The company reported EBITDA of INR 632 million in the quarter ended March 31, 2026, up 39% year-on-year and 28% sequentially.
    Show source
    EBITDA for the quarter stood at INR 632 million, registering a 39% YoY growth and 28% sequential growth on a full-year basis.
  • EBITDA grew by 18% in the year ended March 31, 2026.
    Show source
    EBITDA grew by 18%.
  • The company reported profit after tax of INR 453 million in the quarter ended March 31, 2026, up 69% year-on-year and 5% sequentially.
    Show source
    Profit after tax stood at INR 453 million for the quarter, showcasing a staggering growth of 69% on a YoY basis and 5% sequentially.
Show 19 more statements

Results

  • PAT grew by 30% in the year ended March 31, 2026.
    Show source
    On an annual basis, PAT grew by 30%.
  • PAT margin was 22% in the quarter ended March 31, 2026, and 23% for the year ended March 31, 2026, compared with 21% in FY25.
    Show source
    Consequently, our PAT margin stood at 22% for the quarter and 23% for the full fiscal year, as compared to 21% in FY25.
  • Human Healthcare segment revenue was INR 1,281 million in Q4 FY26, up 24% year-on-year and 33% sequentially.
    Show source
    Our largest and most critical segment revenue for Q4 FY26 stood at INR 1,281 million, marking a 24% YoY growth and 33% sequential increase.
  • Human Healthcare segment grew by 15% on a year-to-date basis in the full year 2026, primarily driven by higher sales volumes in pharma API, biocatalysis, and nutritional business.
    Show source
    For the full year, year-to-date basis, we observed a solid growth of 15%.
  • Animal Healthcare segment revenue was INR 250 million, up 19% year-on-year, 2% sequentially, and 25% on a year-to-date basis.
    Show source
    Animal Healthcare revenue in this segment rose to INR 250 million, delivering a 19% increase YoY, 2% sequential, and 25% on year-to-date basis.
  • Bioprocessing segment grew 17% year-on-year during the quarter, contracted 10% sequentially, and finished the year with 16% year-to-date growth.
    Show source
    Turning to bioprocessing, this segment recorded 17% YoY growth during the quarter despite a 10% sequential contraction, finishing the year with 16% year-to-date growth.
  • Food business grew 20% year-on-year and 19% on a year-to-date basis, predominantly fueling annual growth in bioprocessing.
    Show source
    The annual growth was predominantly fueled by healthy performance of our food business, which grew by 20% YoY and 19% on the year-to-date basis.
  • Non-food business contracted 1% year-on-year and 7% sequentially and remained flat on a year-to-date basis.
    Show source
    Conversely, the non-food business contracted by 1% YoY and 7% sequentially, remaining flat on the year-to-date basis.
  • Scitech's EBITDA stood at INR 104 million as compared to INR 76 million, an increase of 37%, on an annual basis.
    Show source
    And EBITDA stood at INR 104 million as compared to INR 76 million, a 37% increase.
  • Scitech's PAT was INR 45 million as compared to INR 37 million, an increase of 22%, on an annual basis.
    Show source
    And PAT is INR 45 million as compared to INR 37 million, so 22% of increase.
  • Scitech's anti-inflammatory enzyme sales stood at 23% on an annual basis, and its top 10 customers contributed 23% as compared to 22% in FY25.
    Show source
    On an annual basis, our top product, which is anti-inflammatory enzyme sales, stood at 23%, and top 10 customers contributed 23% as compared to 22% in FY25.
  • Scitech's B2C segment was about INR 0.9 million as compared to INR 1.19 million in FY20, and the complete total number was INR 4.37 million for FY26 as compared to INR 4.46 million in FY25.
    Show source
    B2C segment is about INR 0.9 million as compared to INR 1.19 million in FY20, and the complete total number is INR 4.37 million for FY26 as compared to INR 4.46 million in FY25.
  • Standalone R&D expenditure was INR 356 million in FY26 as compared to INR 328 million in FY25.
    Show source
    Our R&D expenditure total on standalone basis is INR 356 million in FY26 as compared to INR 328 million in FY25.
  • Consolidated R&D spend was about 5.6% during Q4 and 5.3% in the corresponding quarter of FY25.
    Show source
    On consolidated basis, our R&D spend is about 5.6% during Q4 and 5.3% in the corresponding quarter of FY25.
  • Serratio business had about 45% year-to-date growth and about 54% quarter-on-quarter growth.
    Show source
    This is Serratio, I think we have on YTD growth about 45%, and QoQ is about 54% growth.
  • The company reversed about INR 16 crore of a provision carried in its books for a litigation matter in FY Q3, and provided for the impact of new labor laws in India on payroll cost.
    Show source
    So about, I think, INR 16 crore was the reversal.
  • Human nutrition contributed 63% of Advanced Enzyme Technologies' total revenue for FY26, with 32% of the business coming from India and 30% from the international market.
    Show source
    So the total is 63% contribution of human nutrition business in our total revenue for FY26.
  • EBITDA margin was about 32% in FY '24 and about 31% in FY '25.
    Show source
    EBITDA margin for both the quarter and the year remains strong at 31%.
  • Animal Healthcare segment growth was mainly driven by increased sales in Asia.
    Show source
    The growth is mainly driven by increased sales in Asia.

What it expects ahead

What management expects

  • The company expects margins to be steady, with 1% or 2% variability always possible.
    Show source
    But if you ask me more or less, we will go with the same margins, and that's what our assumption is.
  • Advanced Enzyme Technologies' R&D revenue expenditure is likely to go up by INR 50 million.
    Show source
    Okay.
  • The company anticipates approval during this year of its anti-inflammatory products filed two years back in European region.
    Show source
    Additionally, we are anticipating approval of our anti-inflammatory products, that we filed two years back in European region, during this year.
  • The company expects overall growth in the double-digit and is aiming for that, but would not comment on a single product or two products.
    Show source
    Mukund Kabra I can't comment on the particular product, but overall, what we expect to grow is in the double-digit and maybe double-digit, and that's, like, what we are aiming for, and that is where all the efforts are there.
  • The company said biocatalysis trials on a few products were going well, and it is looking for moderate growth from this area next year.
    Show source
    And next year, what we are looking at it is some moderate growth coming from this area.

What it is building and selling

Projects and capacity

  • The company will spend an additional INR 50 crores on CapEx this year, and overall CapEx on R&D will be about INR 130 crores.
    Show source
    So I think overall CapEx on R&D will be about INR 130 crores.
  • The company may expand capacity at one of its subsidiary companies and will take a call in September on whether to increase it; its existing infrastructure allows capacity to be increased by 50% right away.
    Show source
    So as of now, currently stand, we do have infrastructure to increase the capacity increment by 50% right away.
  • New R&D center in Nashik is expected to become fully operational in the latter half of this fiscal year, boosting product development bandwidth.
    Show source
    As mentioned in our previous interaction, our new R&D center in Nashik is expected to become fully operational in the latter half of this fiscal year, significantly boosting our product development bandwidth.
  • R&D center is expected to be operational within the next six months of this fiscal year.
    Show source
    As I mentioned that also in my opening remarks, that within next six months, this fiscal year, will be operational into our R&D center, which is one of the largest research-based center in our area so far that I know of.

Segments

  • Human Healthcare division contributed 63% of its total revenue.
    Show source
    Human Healthcare continues to be our flagship division, contributing 63% of our total revenue.
  • Animal Healthcare segment accounted for 13% of its total revenue.
    Show source
    Animal Healthcare account for 13% of our total revenue.

Risks, rules and outside factors

Outside factors

  • The company is still absorbing 10-odd percentage cost from the tariff, and faces a challenge passing this cost on to customers.
    Show source
    Page 17 of 21 Ashish Thavkar So as of now, we are still absorbing, 10-odd percentage cost, right, from the tariff?
  • The company said increasing geopolitical disruption could raise the prices of fuel, salt, solvent, packaging and logistics, potentially creating near-term margin pressures across the industry.
    Show source
    However, we remain vigilant, as increasing geopolitical disruption will escalate the prices of input essentials such as fuel, salt, solvent, packaging, vis-à-vis also logistics, potentially creating near-term margin pressures across the industry.
  • The company said cost was dramatically increasing in the U.S. and discretionary expenses would be under pressure.
    Show source
    But, overall, cost is dramatically increasing.

Everything else said on the call

What management stressed

  • The company said it would limit sharing information about Serratio because the information is frequently requested and creates pressure on the product from competitors.
    Show source
    So maybe we will restrict and have a limitation of sharing of this.
  • The company said it is making changes to become more rapid, broad-based and deeper rather than a commodity. Replaced by a later filing.
    Show source
    And as you can see, we need to be very rapid and very broad -based and deeper rather than a commodity.
  • The company is pursuing innovations rather than just a service industry and is committed to spending a substantial amount of its earnings in the R&D sector. Replaced by a later filing.
    Show source
    And that is what you can see, a lot of registration, a lot of papers, a lot of research, and we are spending substantial -- and we are committed to spend substantial amount of our earnings into the R&D sector.

Other

  • The company maintained a consistent supply track record despite global supply chain challenges. Replaced by a later filing.
    Show source
    Despite these daunting global supply chain challenges, we have maintained a highly consistent supply track record.

What the company said on its earnings call, taken from its own transcript. Not advice.

Questions and answers

  1. Question

    While our Human Nutrition portfolio has done well, we have not lost share in terms of our U.S. exposure also. So, what could be the reason why our gross margin has moderated on QoQ basis this quarter?

    Answer, beni prasad

    Beni Prasad Rauka So, this is mainly what happens is because of the variable cost and fixed cost issue, right? If you have incremental sale, then definitely your gross margins are going to go up because your fixed expenses remains fixed, and you have that operating leverage.

    Answer, mukund kabra

    Mukund Kabra At the same time, we tried to improve the productivity, and there are certain products which we could increase the productivity as well in this quarter. And that's a continuous process with the R&D which comes up. So, it's a combination of both which helps us, even though the costs are written on the higher side because of all of this. Inflations and other thing which is happening with the war, still we could do it because of all the other factors , because there is a constant improvement on the output side as well .

  2. Question

    Abhishek Navalgund Sorry, sir. Actually, what I was trying to ask you is while our EBITDA margin has increased, I think if you see our gross margin number, it has kind of dropped as compared to Q3.

    Answer, mukund kabra

    Mukund Kabra Probably you can take last quarter, we had some extraordinary items on the front.

  3. Question

    Abhishek Navalgund Yeah. So, I'm saying, on the Serratiopeptidase side, the increase that we have seen, this could be a function of some market share gain in the domestic market. So, is it fair to assume that this quarterly run rate will continue going ahead?

    Answer, beni prasad

    Beni Prasad Rauka I think, Mukund will give you the answer.

    Answer, mukund kabra

    Mukund Kabra I won't comment on that, Abhishek. There are always quarter and quarter variability, particularly, but I would say that we'll retain most of it. And it's not only inflammatory products, which we are working on, many other products as well, and those are also contributing.

  4. Question

    Abhishek Navalgund Sure. And you mentioned about the EU approval for the same product. So possible to share, I mean, how big would be the EU market for this product?

    Answer, mukund kabra

    Mukund Kabra Page 5 of 21 It's a novel food which we submitted two years back, and we expect this year it should be approved. If it gets approved, then we will be the only person who can supply that product for next five years or ten years. I need to see exactly what is the time frame which we get, and that should be really interesting for us. I won't be able to give you the numbers, but the interest can be very big.

  5. Question

    Abhishek Navalgund Sure. I'm not asking for any specific guidance, but any aspiration number that you can talk about, let's say, five-year down the line, how do you see this product growing? Whenever we'll get the approval, I mean, post that.

    Answer, mukund kabra

    Mukund Kabra I can't comment on the particular product, but overall, what we expect to grow is in the double-digit and maybe double-digit, and that's, like, what we are aiming for, and that is where all the efforts are there. We won't be able to say about the single product or two products. There are multiple things which we want.

  6. Question

    Abhishek Navalgund Absolutely. My next question is on the current environment, wherein we are seeing inflation and everything. So, I think you talked about fuel, salt, solvents, packaging and logistics. So just would like to know in terms of raw material increase, I guess we are relatively sorted because we procure largely from India. But when it comes to these items like fuel, salt, solvents, packaging, logistics, so how is the pass-through structure like in this quarter? And do you expect some margin pressure because of the full effect getting flowed through in Q1?

    Answer, vasant rathi

    Vasant Rathi Yeah. No. Abhishek, there's always going to be margin pressure. These are all uncertain times with what is going to happen tomorrow with your energy. The industry is very much based upon a lot of energy and other costs, so.

  7. Question

    Abhishek Navalgund Sure. My only point was, basically, is there will be a one quarter, two quarter lag? Is it possible to comment on that, whether we are passing it on or partly passing it on to the customers?

    Answer, vasant rathi

    Vasant Rathi No. Abhishek, it is difficult to pass on very competitive world, global climate. But you try to increase the productivity, increase the efficiencies and try to reduce the cost. There are a lot of mitigating -- a lot of things which we had to work in. Management is very aware of it, trying to compete in the global marketplace. We had to be very efficient.

  8. Question

    Abhishek Navalgund Right. My last question, sir, in terms of guidance, what do you expect in revenue and margins in FY27 and a specific color on U.S. business in particular?

    Answer, vasant rathi

    Vasant Rathi Well, margin and things, as I mentioned before, it's going to be steady, same idea what we are talking about. We wanted to keep this momentum and hopefully build upon it, okay. As far as the U.S. market is concerned, your second part of the question, there is enormous pressure of the inflationary pressures here in the U.S. economy due to energy. Nobody knows what's going to happen in 15 days from now or two months from now. But, overall, cost is dramatically increasing. And, as I mentioned in my comments before, the spending or what you call it, people's discretionary expenses is going to be a lot of pressure on that. So, we'll see how that plays out, okay.

    Answer, vasant rathi

    This is going to be a very challenging year no matter what, okay.

  9. Question

    Kunal Thanvi Hi. Thanks for the opportunity. I had two questions. One was if you can throw some light on, you know, India business growth in terms of pricing and volume. Like, was there an element of price increases because, like, three, four quarters, like, we saw significant price erosion in our largest product? Second question was to Mr. Rathi about your thoughts on buyback of shares. We've seen you know, been buying from open market, and there's a change in the taxation law in India, post which buyback becomes good for the retail investors. Any thoughts if you can share about capital allocation? Because, like, you've also not announced interim dividend this time around. I was curious to

    Answer, vasant rathi

    Vasant Rathi Well, I will try to answer your second question first. You guys are more professionals knowing about the market and prices, but we will be looking at all the necessary options of what is in the best interest of our shareholders and how we increase the value of our shareholders, okay. Regarding the pressure on the -- Kunal Thanvi So sir, is it fair to assume that buyback is also something that you, is like the board is considering?

    Answer, vasant rathi

    Vasant Rathi Yeah. It's a board's priority to look into various different areas, and I'm sure that on the right time board will take a decision, okay. To see whatever, they feel is best interest of the company shareholders. And regarding your first part, Muku nd can probably answer this.

  10. Question

    Kunal Thanvi No. My question, Serratiopeptidase, like, is the growth that we have seen in the Indian business side, is it entirely volume -driven, or there was some price increase that also we saw during the quarter? Because , like, four quarters back or three quarters back, when there was competition in this segment, we had talked about pricing pressure. Is this a reversal of that pricing pressure now coming through, leading to this kind of growth , or it was purely a volume growth that we have seen?

    Answer, mukund kabra

    Mukund Kabra So, let's not look into the quarter-and-quarter basis. I would say some quarters, you will have a higher growth on the particular products, some quarters some other products will have it. In terms of pricing, the pricing is more or less constant. It's more driven by the volume, but at the same time, going forward, we are looking how do we increase the cost and pass on some of the cost, and which we are trying to do from the New Year.

Show 22 more questions
  1. Question

    Kunal Thanvi Sure, fair. Got it. And last question was, we talked about the U.S. market, is that possible slowdown will continue for FY2010, given the geopolitical situation. And then, like at the other end, you've spoken about our aspiration to do a double-digit growth in FY27. Like if you can break down these counters into what are the markets that you believe will kind of support the growth, or to make sure that a flat or a negative U.S. market for FY27 and still we kind of do a double-digit growth. And like, if that happens, what is the second order impact on the margins? Because U.S., I would assume, is a higher-margin business, right? So, if you can talk about these two aspects it will

    Answer, mukund kabra

    We are working on many different fronts. At the same time, when we go into the Indian areas, we are working on, different avenues, different markets we are opening. The last year, we work on many different areas, and probably all the growth will come from all the three segments, including, like, human nutraceutical, food, and like animal feed. So we expect a healthy growth this year from Indian space as well.

  2. Question

    Kunal Thanvi Sure, and is it fair to assume that you would be able to hold on to the margins or, you know, as we've seen in FY26, or because of some pressures and -- the cost pressures in the U.S., there could be an impact on margins?

    Answer, mukund kabra

    Mukund Kabra I wouldn't say that too much of impact. 1% or 2% is always possible, and that's a variability what we have. And I wouldn't like to get into the nitty-gritty of it, maybe, like a Rauka, you can explain. But if you ask me more or less, we will go with the same margins, and that's what our assumption is. But Rauka, you can put give more focus on the margins exactly, what are the numbers saying.

  3. Question

    Rajas Joshi Yeah. Thank you for your opportunity. So, my first question is on the U.S. business. So, if I look at the revenue for this quarter, it is down some 11% in INR terms. Now, given the precision of the INR, in dollar terms, the decline must have been a lot more sharper, so to speak. So just wanted to get a sense on what exactly is happening there. Because I think now, with the tariffs behind as well, we were expecting a recovery in this business. And that is somehow not shown up in the numbers. So, just wanted to get a sense of what exactly is going on, and is it time for us to rethink our strategy in U.S. and probably change the way we are working there?

    Answer, vasant rathi

    Vasant Rathi Rajas, the market is changing in U.S. quite a bit. There is more concentration on the deliverable registration, the studies, et c. And U.S. strategy, changing accordingly. So, market is, as we said before, also very challenging, but we are making very good inroads with the registration in the regulatory areas, as well as in the market segments, okay. So, it is going to be, as I said before, very challenging year, but we are expecting to grow in U.S. market also.

  4. Question

    Rajas Joshi Thank you for the answer, sir. My second question would be on our India business. This quarter has seen a significant increase in sales of about 50%, and they are also been good for us in India. So Sera, obviously, I think there was an earlier mention of Sera volume going up. But outside of Sera, any other products that you would like to call out or any other segment that you would like to possibly call out that is done well for us in India, both in this quarter and for the year as well? Even and then, if you could please also call out your biocatalysis revenue for Q4 and for the full year as well, please.

    Answer, mukund kabra

    Mukund Kabra The revenue, Raukaji, can tell you what exactly the revenue is. But going forward, we do expect, like, a good growth to come from the biocatalysis as well in Indian market. I would like to mention that, not only, the pharma, but this year we grew very well in the food area, as well as in the animal feed area. And even our specialty business grew very well, and we expect that this momentum to continue going forward as well. But if you want a specific biocatalyst number, probably, Raukaji can give you. Yeah, but going forward, we do expect a good Raukaji, can tell you what exactly the revenue is. But going forward, we do expect, like, a good growth to come from the biocatalysis as well in Indian market.

    Answer, mukund kabra

    I would like to mention that, not only, the pharma, but this year we grew very well in the food area, as well as in the animal feed area. And even our specialty business grew very well, and we expect that this momentum to continue going forward as well. But if you want a specific biocatalyst number, probably, Raukaji can give you. Yeah, but going forward, we do expect a good growth coming from those areas as well. Page 8 of 21 Rajas Joshi Understood, sir.

  5. Question

    Rajas Joshi Understood, sir. Thanks a lot. My next question will be on our R&D pipeline. So outside of Sema, which – sorry, Sera which you've already spoken about, the European filing, any other products that are there in pipeline for us, which is still gaining more traction or we are expected to launch soon in this year and then year after that, which you would like to highlight?

    Answer, mukund kabra

    Mukund Kabra This is a continuous process. We are working on many projects as we were talking. Coming this year, probably, in the second half, our R&D new facility should be operational. And after that, we should be able to work on more different products. And because of the competition of the nature, I don't want to now going forward, specify the individual products because that just creates the pressure of the products. So going forward, I will not be like to mention the exact product, but we are working on many different products. That's what I would like to say.

  6. Question

    Rajas Joshi Understood, sir. And, I mean, it seems like the company has turned around in FY26 after a difficult FY25. So, I mean, apart from the revenue outlook which you shared, as the nature of our revenue in some sense also, you know, kind of become more long -term or recurring than it was earlier , is the quality of revenue increased, so to speak?

    Answer, vasant rathi

    Vasant Rathi Quality of revenue is extremely well and very stable.

  7. Question

    Rajas Joshi Understood. Got it. And last question on capital allocation. I think one of the earlier participants also had a question on this. So, I mean, looking at our balance sheet, they were around INR 700 crores of cash. And d espite that, we have canceled the interim dividend. So just wanted to get some thoughts on your thought process regarding that.

    Answer, vasant rathi

    Vasant Rathi That's again, I will say that is the board decisions, which board always evaluate from time to time on how to enh ance our shareholder’s value by different modes and methods, as you guys know very well. So we are al ways, as a company board member , are always looking to see how and where we can do, how we can benefit from this to our shareholders.

  8. Question

    Rajas Joshi Understood, sir. And so, when I brought a question on the fermentation space, so to speak, this would be my last question. You know, there are couple of peers, who actually have now entered, let's say, emerging areas like animal – nope, sorry, non-meat- based proteins, which are also manufactured in the fermentation itself. And those segments also have good growth potential and healthy margin profile as well. So we just want to get a sense on how we are looking at some of these adjacent areas, and are we considering these areas for future expansion as well?

    Answer, vasant rathi

    Vasant Rathi So, I just it is a protein overall category is a growth category, as you all know very well, okay. Non-meat protein is taking some traction as we understand it, and we are continuously working on various different areas to see how we can take the advantage of Page 9 of 21 it, you know, in the whole segment, not only non-meat protein area, but all the entire protein area, so to speak. But, yes, it is a very interesting area, and, obviously, we are always looking into all these growth areas.

  9. Question

    Nikhil Upadhyay Congrats on a good set of numbers for the quarter and the year as a whole. Now , my broader question is, sir, if we look at our growth trajectory in the past since listing, there have been periods when we had very strong growth, then there was a period when the growth would come down to single digit. This time, it seems you are more confident o n the sustain. And so what are the factors or what we have done differently from the past which gives you confidence that this growth momentum can sustain? And in a similar spirit, if we look at it in, this time the growth, even for the year, has been mor e broad-based, like, human nutrition has grown. Animal nutrition has grown. So if

    Answer, vasant rathi

    Vasant Rathi Sure, Nikhil. It's a very good question, and thank you for asking that. As you can see, the growth is broader. And what it wa s is we have to focus on the areas which we want to grow. And initial ly, also from the beginning, we are telling that we have changed the focus on not running after every single thing, but focused on the areas which we are very good at, and we wanted to grow. And it has to become supplemented with lot of research and not necessarily just a commodity product or need to products. So we made a lot of changes in that particular segment.

    Answer, vasant rathi

    Our outlook is more broad -based and long-term rather than the short-term margins. And what you see is that reserves cumulative efforts for some years now that it is paying off this year, in spite of lot of challenges in the global marketplace, okay. And our outlook is a global now. It is not a segmented outlook only. We look at the entire region. World is very fast. It's now coming to the AI world very shortly.

    Answer, vasant rathi

    And as you can see, we need to be very rapid and very broad -based and deeper rather than a commodity. So those are the kind of changes we are making -- we made actually, and continue to make. As I mentioned that also in my opening remarks, that within next six months, this fiscal year, will be operational into our R&D center, which is one of the largest research-based center in our area so far that I know of. So we are going for innovations, as our PM says, you know, rather than just service industry. And that is what you can see, a lot of registration, a lot of papers, a lot of research, and we are spending substantial -- and we are committed to spend substantial amount of our earnings into the R&D sector. Does that give you answers to your question?

  10. Question

    Nikhil Upadhyay Yes, sir. It gives a comprehensive view. I would just want to understand one more point because when we go for a more comprehensive, and in-depth entrance with the customer or entrenchment and more innovation, but there are two aspects which probably can throw light. One is with our existing customers, say, which were present three years back, today, what quantum of business we would have increased with them? And secondly, if we look at the growth beyond our top 10 customers, how would that be? Page 10 of 21 Vasant Rathi Well, you will find that our top 10 customers will be very much evolving and expanding, okay.

    Answer, vasant rathi

    And that is because of what we have, what I said before. And we are very keen on increasing our share of revenues from the existing customers also, which they have already established for so many years. So, there is a lot of changes globally happening right now as you are very well aware, Nikhil. And, obviously, a lot of companies are looking at us also into the different angle, different perspective. So it is an exciting, even though challenging time. And we feel very confident that this really, with a lot of work which we have done in last several years is taking a deep root into it.

  11. Question

    Nikhil Upadhyay Sure, sir. Thanks. Just two questions. One is, sir, see, today, we are almost INR 750, 800 crore kind of a top line company. When we today go to a new customer, the kind of discussion which they are having with us versus when we were a smaller company, say, five or seven years back, today, the kind of projects which we are getting, are they more innovation-driven, or is it more of a, like, second supplier source kind of a replacement which we are doing? So how would you define the kind of work on the R&D we are doing? Is it more newer product and the even the companies are open to give them to us, or is there still some skepticism?

    Answer, vasant rathi

    Vasant Rathi Okay. That's again you're asking very good questions. Well, both. Again, I guess, I will answer you both because new companies, quite a few new companies are approaching us. Old companies are all those companies which are established are checking us out, kind of thing, you know. So, yes, we are working on both. One is we need to continue on getting the revenues from the existing or these new sources, which are just costly one.

    Answer, vasant rathi

    At the same time, we have to establish the new markets, which without innovations, which is a little deep rooted. So the strategies are combination of both.

  12. Question

    Lakshmi Narayanan Sir, two questions. Sir, I noticed that Mr. Roda is moving on, and he has been a big part of our management. I just want to understand, how the organization is maintaining stability and how the organization is actually moving forward, and whether any next person has actually taken a lead in that area.

    Answer, vasant rathi

    Vasant Rathi Mukund, I cannot hear for your questions properly. Maybe you're a little too low sound.

  13. Question

    Lakshmi Narayanan Sir, I understand that Mr. Deepak Roda, who has been part of our team for a long time, had decided to move on. And I just wanted to just understand how that role has been mostly transitioned and if any other person has been replaced, how he has been replaced also?

    Answer, vasant rathi

    Vasant Rathi Well, in an organization, of course, when somebody leaves, such as Mr. Roda, who works for a long time with the company as a part and becomes a part of the company, that hurt overall. But, there is always a management, second-level management, and third- level management, which take care of it.

  14. Question

    Lakshmi Narayanan Okay. Has anyone been appointed, and is the same capacity of having a key role he was in?

    Answer, mukund kabra

    Mukund Kabra So, Lakshmi Narayanan ji, what we did is, like, Mr. Roda was handling some part of Indian business and some part of U.S. business. So, we manage with two different heads at this point of time who are, equally capable and the second line-up, and that's how we are going right now. And I guess, we should be able to do good. We will not be having too much of difficulty going forward as well.

  15. Question

    Lakshmi Narayanan And Mr. Rathi, you are always urged us to think the company on a longer term, not look at quarter, not look at year. But if I just look at our U .S. business from March 22 end to March 26 end, I see that there is a significant divergence from the performance, which is down around 6% on Indian rupee terms , while the currency has actually also depreciated by 22%. So how does the management view this? Is it something which you anticipated or you're happy about? How do you like to measure the -- or how do you like us to look at your U. S. business over a longer period, not necessarily a year or two, but slightly longer?

    Answer, vasant rathi

    Vasant Rathi Overall, we always told you that it is a balanced business, a global business. It is export-driven business as well as local business. So, look, you have to keep and look at it in the same way. Nothing had changed. One year, as I said, various things takes little time to deep root, and that is what we are doing right now, you know, globally, not only in the U.S. market, but global markets all over. So, it is just like somebody said, when one door closes, second, some other door opens.

  16. Question

    Lakshmi Narayanan Got it. And the third question is that, from the Serratio business, right, I mean, how much that did contribute for the full year, and what has been the YoY growth? And as a follow-up on that business, I see that the competition is little muted, if I can understand. So can you just tell me how are you thinking about competitive intensity in the Serratio business? So I think two parts of the question. One is what has been the contribution of Ser ratio for the full year and especially the last year? And how is the competitive intensity? Because I understand that one of the competitors is not selling the product.

    Answer, beni prasad

    Beni Prasad Rauka Yeah. So as Mukund was mentioning, I think this is the last time we will be sharing this number. This is Serratio, I think we have on YTD growth about 45%, and QoQ is about 54% growth. So I think you will all appreciate this information is always being asked and creates of a lot of pressure on the product by the competitors. So maybe we will restrict and have a limitation of sharing of this.

  17. Question

    Shreyans Gathani Hi, good morning, sir. I had a couple of questions. The first one is on the biocatalysis. You know, a few calls ago, you had mentioned that there are some trials going on. So just wanted to get a sense of the overall business and any updates on that.

    Answer, mukund kabra

    Mukund Kabra At this point of time, I would like to say that we are working on few of the products. Trial are going well, but won't be able to comment on the exact number right now. And next year, what we are looking at it is some moderate growth coming from this area.

  18. Question

    That's helpful. The second question was on the gross margin. I think you alluded there's some extraordinary item this quarter. If you could just expand on that, just trying to understand a little more.

    Answer, beni prasad

    Beni Prasad Rauka That was there in FY Q3, right? Q3, we had some exceptional item . That was, I think, one was related to reversal of some provision , which we were carrying in our books for some litigation matter. So that has come in our favo ur. So about, I think, INR 16 crore was the reversal. And in addition to that, we have provided for the impact of the labour laws because in India, you have seen that new labor laws have been enacted. So, impact of those labo ur laws on our payroll cost, so that we have taken into account.

  19. Question

    Shreyans Gathani Okay. Got it. Page 14 of 21 Beni Prasad Rauka In absolute terms, the R&D revenue expenditure is likely to go up by INR 50 million.

    Answer, beni prasad

    Okay. And CapEx is definitely going on. So that will be, again, additional, I think, INR 50 crores we will be spending this year. So I think overall CapEx on R&D will be about INR 130 crores.

  20. Question

    Rohit Ohri Yes, sir. So I have a few questions. While you're becoming a global innovator in this bio-manufacturing platform with certain modes that you have, and we also see this small CWIP or some sort of expansion that is happening, if you can take us through that, this fermentation capacity that we have of around 500 kind of metric cube -- sorry, meter cube capacity. But when do you think that the next round of expansion should come through?

    Answer, mukund kabra

    Mukund Kabra That’s what I said. Like, we might look some capacity expansion into the one of our subsidiary company, and we will take the call in the month of September when we should really increase. So as of now, currently stand, we do have infrastructure to increase the capacity increment by 50% right away. Okay, so we'll take the call as we move forward in this year.

  21. Question

    Ashish Thavkar Yeah. Thanks for the opportunity. Is there any update on where we are in terms of the U.S. tariffs, discussion with the customers? Are they still on the back foot? What's the scene there?

    Answer, vasant rathi

    We just have a challenge how we can pass on this cost to the customers. Page 17 of 21 Ashish Thavkar So as of now, we are still absorbing, 10-odd percentage cost, right, from the tariff?

  22. Question

    Umang Shah Yes, sir.

    Answer, beni prasad

    Beni Prasad Rauka 32% of our business has come from India. I'm talking about human nutrition business, and of our total revenue. 32% from India domestic market, and 30% has come from international market. So the total is 63% contribution of human nutrition business in our total revenue for FY26.

Questions about this call

When was the Advanced Enzyme Technologies Q4 FY26 earnings call transcript filed?
Advanced Enzyme Technologies filed the transcript with the exchange on 15 May 2026. This page is built from that transcript.
What does this page list?
43 statements from the transcript across 7 topics, 31 of them with a figure. Each statement is shown with the transcript sentence it came from.
Are the analysts' questions included?
Yes. 32 questions and management's answers are listed in the order they were asked, as the transcript prints them.
Who wrote this page?
DalalOS Data Desk. Assembled by software from the company's transcript. Not reviewed by a person. How it is made, and what it leaves out, is on the method page linked from the byline.
Research and analysis only, not investment advice. Every statement on this page is the company's own, taken from its transcript; DalalOS adds no view on it and is not a SEBI-registered investment adviser. Something wrong? Report an error.
Advanced Enzyme Technologies Q4 FY26 concall: Advanced Enzyme Technologies Limited expects margins to be steady, with 1% or 2% variability always possible · DalalOS